Tarpon's BioSMB technology can offer the easy scalability and necessary flexibility, efficiency, and proven reduction in manufacturing costs imperative to addressing the challenges faced by the biopharmaceutical manufacturing industry.

Follow-On Biologics and Biosimilars

Traditional batch processes used for the original innovator products are no longer cost competitive today. In order to compete in the biosimilars market, companies need to reduce costs in downstream processing - the manufacturing step that comprises 80% of total manufacturing costs. BioSMB technology can help you achieve the reduction in manufacturing costs paramount in this emerging segment and necessary to commercialization thereby opening the world market to biotherapeutics.

Contract Manufacturing Organizations (CMOs)

BioSMB technology enables CMOs to work on multiple products in the same facility that require flexible and most likely disposable process trains. Whether your company is focused solely on producing drugs for pre-clinical and clinical testing, or product launch and on-going, small-scale production or large-scale biomanufacturing, BioSMB systems provide the scalability and flexibility necessary to realize the benefits of a true multi-product facility of the future.